Skip to main content

Acorda Therapeutics, Inc. (ACOR)

NASDAQ: ACOR · IEX Real-Time Price · USD
4.71 0.05 (1.07%)
Oct 15, 2021 4:00 PM EDT - Market closed
Market Cap52.39M
Revenue (ttm)151.90M
Net Income (ttm)-132.02M
Shares Out9.99M
EPS (ttm)-14.72
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume111,181
Open4.73
Previous Close4.66
Day's Range4.62 - 4.90
52-Week Range3.27 - 9.84
Beta0.58
AnalystsBuy
Price Target10.00 (+112.3%)
Est. Earnings DateNov 2, 2021

About ACOR

Acorda Therapeutics, Inc., a biopharmaceutical company, develops and commercializes therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), an oral drug to improve walking in patients with multiple sclerosis (MS); Selincro for the treatment of alcohol dependence; and Inbrija for the treatment of OFF periods in Parkinson's disease in Europe. It also markets Ampyra as Fampyra in Europe, Asia, and the Americas. In addition, the company develops ARCUS product for the treatment of acute migrain; rHIgM22...

IndustryBiotechnology
IPO DateFeb 10, 2006
CEORon Cohen
Employees167
Stock ExchangeNASDAQ
Ticker SymbolACOR
Full Company Profile

Financial Performance

In 2020, ACOR's revenue was $152.97 million, a decrease of -20.50% compared to the previous year's $192.41 million. Losses were -$99.59 million, -63.51% less than in 2019.

Financial Statements

Analyst Forecast

According to 3 analysts, the average rating for ACOR stock is "Buy." The 12-month stock price forecast is 10.00, which is an increase of 112.31% from the latest price.

Price Target
$10.00
(112.31% upside)
Analyst Consensus: Buy

News

Acorda Therapeutics Announces Corporate Restructuring, Management Changes

ARDSLEY, N.Y.--(BUSINESS WIRE)--Acorda Therapeutics Announces Corporate Restructuring, Management Changes

1 month ago - Business Wire

Acorda Therapeutics (ACOR) Reports Q2 Loss, Tops Revenue Estimates

Acorda (ACOR) delivered earnings and revenue surprises of -9.57% and 6.16%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

2 months ago - Zacks Investment Research

Acorda Therapeutics Reports Second Quarter 2021 Financial Results

ARDSLEY, N.Y.--(BUSINESS WIRE)--Acorda Therapeutics Reports Second Quarter 2021 Financial Results

2 months ago - Business Wire

Acorda Second Quarter 2021 Update: Webcast/Conference Call Scheduled for August 5, 2021

ARDSLEY, N.Y.--(BUSINESS WIRE)--Acorda Second Quarter 2021 Update: Webcast/Conference Call Scheduled for August 5, 2021

2 months ago - Business Wire

Will Acorda Therapeutics (ACOR) Report Negative Q2 Earnings? What You Should Know

Acorda (ACOR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

2 months ago - Zacks Investment Research

Acorda Therapeutics Shares Gains On Spain Distribution Pact For Parkinson's Med

Acorda Therapeutics Inc (NASDAQ: ACOR) has entered into distribution and supply agreements with Esteve Pharmaceuticals S.A. to commercialize Inbrija 33 mg (levodopa inhalation powder, hard capsules) in ...

2 months ago - Benzinga

Acorda Therapeutics Announces Agreement to Commercialize INBRIJA® in Spain

ARDSLEY, N.Y.--(BUSINESS WIRE)--Acorda Therapeutics Announces Agreement to Commercialize INBRIJA® in Spain

2 months ago - Business Wire

Acorda Therapeutics Announces Repayment of Convertible Senior Notes

ARDSLEY, N.Y.--(BUSINESS WIRE)--Acorda Therapeutics Announces Repayment of Convertible Senior Notes

4 months ago - Business Wire

Acorda Therapeutics (ACOR) Reports Q1 Loss, Tops Revenue Estimates

Acorda (ACOR) delivered earnings and revenue surprises of 3.15% and 30.30%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

5 months ago - Zacks Investment Research

Acorda Therapeutics Reports First Quarter 2021 Financial Results

ARDSLEY, N.Y.--(BUSINESS WIRE)--Acorda Therapeutics Reports First Quarter 2021 Financial Results

5 months ago - Business Wire

Acorda Therapeutics First Quarter 2021 Update: Webcast/Conference Call Scheduled for May 6, 2021

ARDSLEY, N.Y.--(BUSINESS WIRE)--Acorda Therapeutics First Quarter 2021 Update: Webcast/Conference Call Scheduled for May 6, 2021

5 months ago - Business Wire

All You Need to Know About Acorda (ACOR) Rating Upgrade to Strong Buy

Acorda (ACOR) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

5 months ago - Zacks Investment Research

Celebrity Chef Zarela Martinez Partners with Acorda Therapeutics on the launch of “A Taste for Life with Zarela℠”

ARDSLEY, N.Y.--(BUSINESS WIRE)--Celebrity Chef Zarela Martinez Partners with Acorda Therapeutics on the launch of “A Taste for Life with Zarela”.

6 months ago - Business Wire

Has Acorda Therapeutics (ACOR) Outpaced Other Medical Stocks This Year?

Is (ACOR) Outperforming Other Medical Stocks This Year?

7 months ago - Zacks Investment Research

Acorda Therapeutics to Present at H.C. Wainwright Global Life Sciences Virtual Conference

ARDSLEY, N.Y.--(BUSINESS WIRE)--Acorda Therapeutics to Present at H.C. Wainwright Global Life Sciences Virtual Conference

7 months ago - Business Wire

Acorda Therapeutics (ACOR) Reports Q4 Loss, Tops Revenue Estimates

Acorda (ACOR) delivered earnings and revenue surprises of -68.92% and 12.24%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

7 months ago - Zacks Investment Research

Acorda Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2020 Financial Results

ARDSLEY, N.Y.--(BUSINESS WIRE)--Acorda Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2020 Financial Results

7 months ago - Business Wire

Acorda Fourth Quarter/Year End 2020 Update: Webcast/Conference Call Scheduled for March 4, 2021

ARDSLEY, N.Y.--(BUSINESS WIRE)--Acorda Fourth Quarter/Year End 2020 Update: Webcast/Conference Call Scheduled for March 4, 2021

7 months ago - Business Wire

Acorda Therapeutics (ACOR) Sees Hammer Chart Pattern: Time to Buy?

Acorda Therapeutics (ACOR) has been struggling lately, but the selling pressure may be coming to an end soon.

7 months ago - Zacks Investment Research

Acorda Therapeutics Announces Departure of Chief, Business Operations

ARDSLEY, N.Y.--(BUSINESS WIRE)--Acorda Therapeutics Announces Departure of Chief, Business Operations

7 months ago - Business Wire

Acorda Therapeutics Announces Completion of Sale of Manufacturing Operations to Catalent

ARDSLEY, N.Y.--(BUSINESS WIRE)--Acorda Therapeutics Announces Completion of Sale of Manufacturing Operations to Catalent

8 months ago - Business Wire

Acorda (ACOR) to Report Q4 Earnings: What's in the Cards?

During Acorda's (ACOR) upcoming Q4 earnings call, investor focus will be on the sales uptake of its Parkinson's disease drug, Inbrija.

8 months ago - Zacks Investment Research

Acorda (ACOR) Soars on Sale of Manufacturing Unit for Inbrija

Acorda (ACOR) inks an agreement to sell its Inbrija manufacturing operations in Chelsea for $80 million to Catalent. The company also announces a corporate restructuring plan to save costs.

9 months ago - Zacks Investment Research

Acorda Therapeutics Announces Agreement for Sale of Manufacturing Operations and Long-Term Global Supply Agreement fo...

ARDSLEY, N.Y.--(BUSINESS WIRE)--Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced that it has entered into a definitive agreement to sell its INBRIJA manufacturing operations in Chelsea, Massachu...

9 months ago - Business Wire

Acorda Therapeutics to Present at 39th Annual J.P. Morgan Health Care Conference

ARDSLEY, N.Y.--(BUSINESS WIRE)--Acorda Therapeutics, Inc. (NASDAQ: ACOR) announced that Ron Cohen, M.D., President and Chief Executive Officer, will present at the 39th Annual J.P. Morgan Health Care Co...

9 months ago - Business Wire